Crizanlizumab-tmca 10 mg/ML
RxNorm 2262422

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2262422 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: crizanlizumab-tmca 10 mg/ML.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDC
Crizanlizumab-tmca 10 mg/ML
AUI:11801081
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDCPrescribable

Semantic Clinical Drug Component (SCDC):
Crizanlizumab-tmca 10 mg/ML
(Atom ID: 11801081)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
crizanlizumab-tmca 10 MG/ML
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2262422
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11801081
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDC
Semantic Clinical Drug Component (Ingredient + Strength)
Source Code
2262422
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN BOSS STRENGTH DENOM UNIT
ML
RXN Boss Strength Denom Unit
RXN BOSS STRENGTH DENOM VALUE
1
RXN Boss Strength Denom Value
RXN BOSS STRENGTH NUM UNIT
MG
RXN Boss Strength Num Unit
RXN BOSS STRENGTH NUM VALUE
10
RXN Boss Strength Num Value
RXN IN EXPRESSED FLAG
P
Strength Expressed As Precise Flag
RXN STRENGTH
10 MG/ML
Strength plus unit of SCDC

Patient Education

Crizanlizumab-tmca Injection


Crizanlizumab-tmca injection is used to reduce the number of pain crises (sudden, severe pain that may last several hours to several days) in adults and children 16 years of age and older with sickle cell disease (an inherited blood disease). Crizanlizumab-tmca is in a class of medications called monoclonal antibodies. It works by blocking certain blood cells from interacting.
[Learn More]


* Please review the disclaimer below.